Meeting
2023 ASCO Annual Meeting
FOXC1 expression in meningiomas.
Authors
Michelle Wedemeyer
Nationwide Children’s Hospital, Columbus, OH
Michelle Wedemeyer , Joanne Xiu , Phillip Walker , Jasmeet Kaur , Christian Davidson , Manmeet Singh Ahluwalia , Ashley Love Sumrall , Gabriel Zada
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Non-Glioma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2074)
DOI
10.1200/JCO.2023.41.16_suppl.2074
Abstract #
2074
Poster Bd #
431
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
First Author: Weimin Li
Poster
2023 ASCO Annual Meeting
A study of tumor neoantigen burden and HLA-LOH by whole-exome sequencing to characterize immune biomarkers of lung cancer.
First Author: Wei Wang
Poster
2021 ASCO Annual Meeting
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.
First Author: Hsiang-fong Kao
Poster
2020 ASCO Virtual Scientific Program
Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance.
First Author: Krystle Nomie